OSI-774 OSI Pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 2, Issue 2, 2001, Pages 298-304

  Norman, P ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; BIBX 1382; CANERTINIB; CISPLATIN; CL 387785; CP 373420; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TUMOR LEVEL; EXPERIMENTAL MODEL; HEAD AND NECK CANCER; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HEAD AND NECK NEOPLASMS; HUMANS; ONCOGENES; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035113630     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Annual Report 1996 - Oncogene Science Inc
2. American Association for Cancer Research 1997: Progress and new hope in the fight against cancer
3. Tissue distribution of CP-358774, a selective and potent EGF receptor tyrosine kinase inhibitor in HN5 tumor-bearing, athymic nu/nu (nude) mice
4. Pre-clinical safety assessment of CP-358774, an epidermal growth factor receptor tyrosine kinase inhibitor
5. Induction of cell cycle arrest by inhibitors of epidermal growth factor receptor (EGFR) kinase activity
6. Pharmacokinetics and metabolism of CP-358,744, a potent and selective EGF receptor tyrosine kinase inhibitor
7. Inhibitors of tyrosine kinase
8. OSI Pharmaceuticals Inc
9. Medicinal Chemistry in Eastern England, Ninth Symposium University of Hertfordshire, Hatfield, UK
10. CP-358,774, a selective EGFR kinase inhibitor, inhibits phosphorylation of SHC and retinoblastoma protein in human tumor xenografts
11. Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
12. Innovation, focus and new drugs to sustain Pfizer's growth into the 21st century, Steere tells analysts/Company anticipates initial marketing approval for four new chemical entities over the next two years
13. Tyrosine kinase inhibitors in cancer treatment (Part II)
14. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
15. Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor CP-358774: A phase I and pharmacokinetic study
16. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor CP-358774 in patients with advanced solid tumors
17. OSI Pharmaceuticals provides update on anticancer programs with Pfizer
18. Small molecule inhibitors of receptor tyrosine kinases
19. OSI Pharmaceuticals gains full development and marketing rights for Pfizer's anticancer compound, CP-358,774 (OSI-774) - FTC consent decree requires Pfizer to divest CP-358,774 (OSI-774) in merger with Warner-Lambert
20. OSI looks to CRO to develop oncologic agent following Pfizer divestiture
21. OSI Pharmaceuticals announces formal transfer of IND for OSI-774 and provides clinical update
22. OSI Pharmaceuticals updates phase II data for the company's lead anticancer compound, OSI-774 - Data for patients with non-small cell lung and head and neck cancers presented at the European Organization for the Research and Treatment of Cancer (EORTC) symposium in Amsterdam
23. Synthesis of 4-(phenylamino)pyrimidine derivatives as ATP-competitive protein kinase inhibitors with potential for cancer chemotherapy
24. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
25. Investigation of the effects of CP-358,774 on various human tumor specimens taken directly from patients
26. 18FDG-PET evaluation of patients treated with the epidermal growth factor (EGFR) tyrosine kinase (TK) inhibitor, CP-358,774
27. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
28. A phase II, multi-center study of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI), CP-358,774, in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN)
29. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases
30. EGF receptor antagonists: An important new class of anticancer
31. Strengthening of Roche's oncology franchise - Roche and Genentech sign agreement with OSI to develop and commercialize OSI's novel anticancer drug OSI-774
32. OSI Pharmaceuticals, Genetech and Roche to develop and commercialize OSI-774, OSI's lead cancer drug